Nuclear Export Gone Rogue: XPO1's Chromatin Side Hustle Fuels Leukemia [0.03%]
rogue核输出：XPO1的染色质旁业推动白血病的发展
Drew J Adams
Drew J Adams
Exportin-1 (XPO1/CRM1) is a validated target in hematologic malignancies best studied for its role in mediating nuclear export. In this issue of Blood Cancer Discovery, Barajas and colleagues reveal that UBTF tandem duplications found in ac...
Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironment [0.03%]
髓外多发性骨髓瘤肿瘤微环境中T和NK细胞的组成及功能状态
Anjana Anilkumar Sithara,Veronika Kapustova,David Zihala et al.
Anjana Anilkumar Sithara et al.
Extramedullary multiple myeloma (EMM) is a high-risk feature of multiple myeloma (MM) associated with increased resistance to treatments, including modern immunotherapies, and shorter survival. Composition and functional state of immune cel...
Lillian L Siu;AACR Cancer Progress Report Steering Committee
Lillian L Siu;AACR Cancer Progress Report Steering Committee
The state of the blood cancer field and its toll on patient mortality and morbidity, adapted from the 15th edition of the annual AACR Cancer Progress Report (https://cancerprogressreport.aacr.org/progress/), is presented to the US Congress ...
The Link between Modifiable Risk Factors and Myeloid Disorders-From Plate to Pathogenesis [0.03%]
骨髓增生性肿瘤危险因素及发病机制的链式反应模型
Joshua T Weinreb,Omar Abdel-Wahab,Urvi A Shah
Joshua T Weinreb
Clonal hematopoiesis of indeterminate potential, myelodysplastic syndromes, and acute myeloid leukemia are myeloid cell disorders that exist on a spectrum. Modifiable risk factors, including obesity, insulin resistance, physical activity, d...
PKCβ inhibitor MS-553 displays preclinical efficacy in both treatment-naïve and BTK inhibitor-resistant Chronic Lymphocytic Leukemia [0.03%]
PKCβ抑制剂MS-553对既往未治疗和BTK抑制剂耐药的慢性淋巴细胞白血病均具有临床前疗效
Britten K Gordon,Elizabeth M Muhowski,Jyotsana Singh et al.
Britten K Gordon et al.
Inhibition of the tyrosine kinase BTK is a major therapeutic strategy for treating B-cell malignancies, including chronic lymphocytic leukemia (CLL). However, resistance can emerge when tumor cells acquire mutations that abrogate drug bindi...
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell Lymphoma [0.03%]
口服CELMoD剂戈沙瑞莫通过靶向IKZF1/3治疗弥漫性大B细胞淋巴瘤
Zhongying Mo,Lynda Groocock,Scott Wood et al.
Zhongying Mo et al.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease with limited treatment options and poor prognosis, especially for patients refractory to standard therapies. We report the discovery of golcadomide (CC-99282),...
Tandem duplications in UBTF create XPO1-dependent nuclear export signals that reveal a leukemic therapeutic dependency [0.03%]
UBTF串联重复通过XPO1依赖的核输出信号来揭示白血病治疗靶点
Juan M Barajas,Aaron H Phillips,Jina Wang et al.
Juan M Barajas et al.
UBTF tandem duplications (UBTF-TDs) define a high-risk molecular subtype of acute myeloid leukemia (AML). While menin inhibitors show therapeutic promise in UBTF-TD AMLs, acquired resistance remains a challenge. Here, we used proteomic, epi...
Intra-leukemic interferon signaling suppresses expansion and mediates chemoresistance in human AML [0.03%]
白血病细胞内的干扰素信号传导可抑制急性髓系白血病的癌细胞增殖并介导其耐药性
Daiki Karigane,Amy C Fan,Toshinobu Nishimura et al.
Daiki Karigane et al.
Intra-tumoral heterogeneity can impact the competitive fitness and chemoresistance of individual cancer cells. In acute myeloid leukemia (AML), both genetic and functional heterogeneity contribute to chemoresistance, resulting in relapse. W...
CD70-Targeting CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma Models [0.03%]
针对CD70的CAR-NK细胞克服了高危多发性骨髓瘤模型中BCMA下调并改善生存率
Paul Lin,Sunil Acharya,Francia Reyes-Silva et al.
Paul Lin et al.
CD70 is highly expressed in many cancers, including multiple myeloma (MM). We show in two cohorts of patients with MM that CD70 is elevated in several high-risk disease categories and correlates with poor survival. These findings were valid...
A pharmacokinetic/pharmacodynamic model predicts tumor debulking improves CAR T-cell efficacy in Large B-Cell Lymphoma [0.03%]
药代动力学/药效学模型预测肿瘤减瘤可提高CAR-T细胞在大B细胞淋巴瘤中的疗效
Amy E Pomeroy,Brian J Sworder,Deborah Plana et al.
Amy E Pomeroy et al.
Chimeric Antigen Receptor (CAR) T-cells produce durable remissions in some large B-cell lymphoma patients, but outcomes are poor in patients with large tumor burdens or limited CAR T-cell expansion. To understand these relationships and exp...